Arcutis Biotherapeutics, Inc. (ARQT) shares rallied 11.2% in the last trading session to close at $26.14. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 11.4% loss over the past four weeks.
The recent price rise can be attributed to growing investor confidence related to the sales performance of the company’s flagship product, Zoryve (topical roflumilast), a highly potent and selective phosphodiesterase-4 inhibitor marketed in the United States in both cream and foam formulations. Zoryve is approved across three major inflammatory dermatological conditions—plaque psoriasis, atopic dermatitis, and seborrheic dermatitis. Arcutis recorded product sales worth $235.3 million in the first half of 2026, surging nearly 62% year over year.
This company is expected to post quarterly earnings of $0.17 per share in its upcoming report, which represents a year-over-year change of +183.3%. Revenues are expected to be $141.64 million, up 42.8% from the year-ago quarter.
Earnings and revenue growth expectations certainly give a good sense of the potential strength in a stock, but empirical research shows that trends in earnings estimate revisions are strongly correlated with near-term stock price movements.
For Arcutis Biotherapeutics, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on ARQT going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Arcutis Biotherapeutics is a member of the Zacks Medical - Biomedical and Genetics industry. One other stock in the same industry, TG Therapeutics (TGTX), finished the last trading session 5.3% higher at $55.85. TGTX has returned 5.5% over the past month.
TG Therapeutics' consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.36. Compared to the company's year-ago EPS, this represents a change of -85.2%. TG Therapeutics currently boasts a Zacks Rank of #5 (Strong Sell).
Beyond Nvidia: AI's Second Wave Is Here
The AI revolution has already minted millionaires. But the stocks everyone knows about aren't likely to keep delivering the biggest profits. AI’s second wave is moving from infrastructure to implementation and these companies are at the forefront of this transition, positioned to become what Amazon and Google were to the internet era.
See Stocks Now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Arcutis Biotherapeutics, Inc. (ARQT): Free Stock Analysis Report
TG Therapeutics, Inc. (TGTX): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).